| First Author | Hopp K | Year | 2022 |
| Journal | iScience | Volume | 25 |
| Issue | 1 | Pages | 103697 |
| PubMed ID | 35059607 | Mgi Jnum | J:337328 |
| Mgi Id | MGI:6857320 | Doi | 10.1016/j.isci.2021.103697 |
| Citation | Hopp K, et al. (2022) Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience 25(1):103697 |
| abstractText | Progression of autosomal dominant polycystic kidney disease (ADPKD) is modified by metabolic defects and obesity. Indeed, reduced food intake slows cyst growth in preclinical rodent studies. Here, we demonstrate the feasibility of daily caloric restriction (DCR) and intermittent fasting (IMF) in a cohort of overweight or obese patients with ADPKD. Clinically significant weight loss occurred with both DCR and IMF; however, weight loss was greater and adherence and tolerability were better with DCR. Further, slowed kidney growth correlated with body weight and visceral adiposity loss independent of dietary regimen. Similarly, we compared the therapeutic efficacy of DCR, IMF, and time restricted feeding (TRF) using an orthologous ADPKD mouse model. Only ADPKD animals on DCR lost significant weight and showed slowed cyst growth compared to ad libitum, IMF, or TRF feeding. Collectively, this supports therapeutic feasibility of caloric restriction in ADPKD, with potential efficacy benefits driven by weight loss. |
